Full Press Release Details
SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that management will participate in the Jefferies 2025 Global Healthcare Conference. Details are as follows:
Format: Fireside ChatDate: Thursday, June 5, 2025Time: 1:25 PM ETLocation: New York, NYWebcast link: Availablehere
The live webcast of the Jefferies fireside chat can be accessed by visiting the Investors section of ALX Oncology’s website atwww.alxoncology.comunder theEventssection of the Events and Presentations tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.
About ALX OncologyALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025. More information is available atwww.alxoncology.comand on LinkedIn@ALX Oncology.